Celularity (CELU) vs Context Therapeutics (CNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Celularity (CELU) has outperformed Context Therapeutics (CNTX) over the past year, losing 73.5% versus a loss of 85.3%. Over five years, CNTX leads with a -96.9% price change compared with -99.3% for CELU. Celularity is the larger company by market cap ($15.0 million vs $14.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELU | CNTX |
|---|---|---|
| Share price | $0.463 | $0.16 |
| Market cap | $15.02M | $14.70M |
| 1-day change | -1.05% | -5.10% |
| YTD return | -58.29% | -89.12% |
| 1-year return | -73.54% | -85.32% |
| 5-year return | -99.31% | -96.86% |
| EPS (TTM) | $-1.69 | $-0.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $26.55M | — |
| Revenue growth (YoY) | -51.03% | — |
| Net income (latest FY) | $-91.72M | $-36.12M |
| Gross margin | 24.39% | — |
| Operating margin | -230.92% | — |
| Net margin | -345.45% | — |
| 52-week high | $2.55 | $3.62 |
| 52-week low | $0.42 | $0.153 |
| Distance from 52-week high | -81.84% | -95.58% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2418.75% |
| Average volume | 3.95M | 1.42M |
| Shares outstanding | 32.45M | 91.88M |
| Employees | 115 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELU has outperformed CNTX by 11.8 percentage points over the past year.
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
CELU vs CNTX FAQ
Which is bigger, Celularity or Context Therapeutics?
Celularity (CELU) is larger, with a market capitalization of $15.02M compared with $14.70M for Context Therapeutics (CNTX).
Which stock has performed better over the past year, CELU or CNTX?
CELU returned -73.54% over the past 12 months, compared with -85.32% for CNTX (price return, excluding dividends). Past performance does not predict future results.
Are Celularity and Context Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.